Nick Pizzie, the Chief Financial Officer of Axsome Therapeutics, Inc. (NASDAQ:AXSM), recently executed a series of stock transactions according to a Form 4 filing with the Securities and Exchange ...
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target raised by equities research analysts at Wells Fargo ...
Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Axsome Therapeutics in a research report issued ...
Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...